ASX:VIT

ASX ANNOUNCEMENT

27 NOVEMBER 2026

Results of 2026 Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**) at its 2026 Annual General Meeting (**AGM**) held today.

All resolutions put to the AGM were passed on a poll.

**** ENDS ****

Authorised by

Authorised for release to the ASX by the Company Secretary of Vitura Health Limited.

Contact

Vitura Health Limited

Justin James
CEO
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

About Vitura Health Limited (ASX: VIT)

- www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com

Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes roughly 600 therapeutic product and device SKUs within Australia from roughly 70 international and domestic brands.

- www.canview.com.au

Canview was developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration software owned and operated by Vitura. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the in-house integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the roughly 4,700 Australian pharmacies with accounts on Canview for dispensing.

• www.doctorsondemand.com.au

The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health and medicated weight loss.

• www.cortexa.com.au

The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.

• www.candor.com.au

The Company owns Candor Medical that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis and other speciality products and services.

• www.releaf.com.au

The Company owns a 42.5% equity interest in Flora Holdings Pty Ltd, a joint venture that owns and operates a series of medicinal cannabis clinics operating under the Releaf brand.

Vitura Health Limited
Annual General Meeting
Friday, 27 November 2026
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of the Remuneration Report	Ordinary	297,036,422 99.40%	1,658,910 0.55%	142,257 0.05%	119,878,998	297,178,679 99.44%	1,658,910 0.56%	119,878,998	Carried
2 Re-election of Daniel Birch as a Director	Ordinary	416,571,763 99.91%	201,398 0.05%	147,257 0.04%	6,790,667	416,719,020 99.95%	201,398 0.05%	6,790,667	Carried
3 Approval of 10% Placement Capacity	Special	Resolution withdrawn				Resolution withdrawn			Not Applicable
4 Renewal of Proportional Takeover Provision in Constitution	Special	418,435,409 99.94%	137,334 0.03%	142,257 0.03%	4,996,085	418,577,666 99.97%	137,334 0.03%	4,996,085	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Resolution proposed but not put to the meeting

Resolution	Reason for not putting the resolution to the meeting
3 Approval of 10% Placement Capacity	Refer to the ASX announcement released on the 20 November 2026